2023 Women’s Masterclass On Demand |
- 12.00 ACPE Pharmacy
- 12.00 AMA PRA Category 1 Credit™
- 12.00 ANCC
- 12.00 Participation
|
Enduring |
|
$0.00 |
Sleep, Sodium, and CVD - A Cardiology Perspective |
- 2.25 ACPE Pharmacy
- 2.25 AMA PRA Category 1 Credit™
- 2.25 ANCC
- 2.25 Participation
|
Enduring |
|
$0.00 |
New Hope on the Horizon - Advances in the Diagnosis and Treatment of Idiopathic Hypersomnia |
- 1.75 ACPE Pharmacy
- 1.75 AMA PRA Category 1 Credit™
- 1.75 ANCC
- 1.75 Participation
|
Enduring |
|
$0.00 |
18th Annual CMHC On Demand |
- 19.25 CDE
- 19.25 ACPE Pharmacy
- 19.25 AMA PRA Category 1 Credit™
- 19.25 ANCC
- 19.25 Participation
|
Enduring |
|
$0.00 |
Tackling the Disproportionate Burden of Resistant Hypertension in Black Adults |
- 1.00 CDE
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
|
Enduring |
|
$0.00 |
Clinical Brief: The Burden of Resistant Hypertension in Women - Novel and Emerging Approaches to Improve Outcomes |
- 0.75 ACPE Pharmacy
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Participation
|
Enduring |
|
$0.00 |
Webcast: Addressing and Treating Iron Deficiency to Improve Symptoms and Outcomes in Patients with Heart Failure |
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
|
Enduring |
|
$0.00 |
Challenges and Solutions in Lipid-Lowering Therapy in Women: From Gaps to Practice-Changing Advances |
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 Participation
|
Enduring |
|
$0.00 |
Escape Room Experience: Individualizing Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes |
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
|
Enduring |
|
$0.00 |
Breaking Through Inertia: How to Initiate and Maintain Insulin Therapy in Patients with Type 2 Diabetes |
- 1.50 AAFP
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation
|
Enduring |
|
$0.00 |
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis |
- 0.75 ACPE Pharmacy
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Participation
|
Enduring |
|
$0.00 |
Exploring Novel Strategies for LDL-C Combination Therapy to Decrease ASCVD Risk: A Paradigm Shift |
- 1.50 CDE
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 Participation
|
Enduring |
|
$0.00 |
Understanding the Role of Lp(a) as a CV Risk Marker to Therapeutic Target in the Prevention of ASCVD |
- 1.50 CDE
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 Participation
|
Enduring |
|
$0.00 |
Ace the Case Challenge Series: Exploring Novel Strategies for LDL-C Combination Therapy to Decrease ASCVD Risk |
- 0.75 ACPE Pharmacy
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Participation
|
Enduring |
|
$0.00 |
Ace the Case Challenge Series: The Intersection of MASH and Cardiometabolic Risk |
- 0.50 CDE
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation
|
Enduring |
|
$0.00 |